Document is current
Any future updates will be listed below
-
Authors
Fallarino, Francesca https://orcid.org/0000-0002-8501-2136
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
- License Information
-
More Information
Article History
Accepted: 19 August 2025
First Online: 22 September 2025
Competing interests
: F.F. declares no competing interests. C.U.B. has advisory roles at Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab, Pierre Fabre and Hexal/Sandoz, all of which are paid to the Netherlands Cancer Institute (NKI); and at Third Rock Ventures. C.U.B./NKI receives research funding from Bristol-Myers Squibb, Novartis, NanoString, 4SC, and Senya Therapeutics. C.U.B. has stock ownership in and is a co-founder of Flindr Therapeutics, a spin-off of the NKI to develop clinical TNF sensitizers. C.U.B. holds patents (including submitted) WO 2021/177822 A1, N2027907 and P091040NL2.
